

**FITC anti-human CD326 (EpCAM)**

**Catalog # / Size:** 2221015 / 25 tests  
2221020 / 100 tests

**Clone:** 9C4

**Isotype:** Mouse IgG2b,  $\kappa$


**Immunogen:** DU.4475 breast carcinoma

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human colon carcinoma cell line HT29 stained with 9C4 FITC

**Applications:**

**Applications:** Immunofluorescence

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunofluorescence and immunohistochemistry<sup>3</sup>.

**Application References:**

1. Lammers R, *et al.* 2002. *Exp. Hematol.* 30:537.
2. Schultz LD, *et al.* 2010. *P. Natl. Acad. Sci. USA* 107:13022. [PubMed](#)
3. Human Protein Atlas <http://www.proteinatlas.org/ENSG00000119888/antibody> (IHC)

**Description:** CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythropoiesis. CD326 functions as a homotypic calcium-independent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.

**Antigen References:**

1. Strnad J, *et al.* 1989. *Cancer Res.* 49:314.
2. Munz M, *et al.* 2004. *Oncogene* 23:5748.
3. Rao CG, *et al.* 2005. *Int. J. Oncol.* 27:49.